$3.33
-7.5%Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
Last Annual Value
1.00M
3-Year CAGR
%
5-Year CAGR
%
10-Year CAGR
%
| Company | Long Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
![]() Perspective Therapeutics, Inc. AMEX:CATX | 1.00M | -15.7% | N/A | N/A | |
![]() TriSalus Life Sciences, Inc. NASDAQ:TLSI | 34.27M | N/A | N/A | N/A | |
![]() Electromed, Inc. AMEX:ELMD | 0.00 | N/A | N/A | N/A | |
![]() MaxCyte, Inc. NASDAQ:MXCT | 0.00 | N/A | N/A | N/A | |
![]() Invivyd, Inc. NASDAQ:IVVD | 1.18M | N/A | N/A | N/A | |
![]() Neuronetics, Inc. NASDAQ:STIM | 65.81M | 3.5% | 13.2% | 15.4% | |
![]() Solana Company NASDAQ:HSDT | 0.00 | N/A | N/A | N/A |
Continue your CATX research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.